Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Anti-von Willebrand Factor Nanobody, Caplacizumab
(Cablivi (TN))		2件: Caplacizumab (Cablivi),
Von Willebrand factor human		1件: Caplacizumab (Cablivi (TN)) 💬 1件: VWF 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64 💬
2Anti-von Willebrand Factor Nanobody, INN = Caplacizumab
(Cablivi (TN))		2件: Caplacizumab (Cablivi),
Von Willebrand factor human		1件: Caplacizumab (Cablivi (TN)) 💬 1件: VWF 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64 💬
3CABLIVI1件: Caplacizumab (Cablivi)1件: Caplacizumab (Cablivi (TN)) 💬 1件: VWF 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64 💬
4Cablivi®1件: Caplacizumab (Cablivi)1件: Caplacizumab (Cablivi (TN)) 💬 1件: VWF 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64 💬
5CAPLACIZUMAB
(Cablivi (TN))		1件: Caplacizumab (Cablivi)1件: Caplacizumab (Cablivi (TN)) 💬 1件: VWF 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64 💬
6Caplacizumab (ALX-0081)
(Cablivi (TN))		1件: Caplacizumab (Cablivi)1件: Caplacizumab (Cablivi (TN)) 💬 1件: VWF 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64 💬
7Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081)
(Cablivi (TN))		2件: Caplacizumab (Cablivi),
Von Willebrand factor human		1件: Caplacizumab (Cablivi (TN)) 💬 1件: VWF 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64 💬
8Caplacizumab (an anti-von Willebrand Factor Nanobody)
(Cablivi (TN))		2件: Caplacizumab (Cablivi),
Von Willebrand factor human		1件: Caplacizumab (Cablivi (TN)) 💬 1件: VWF 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64 💬